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glioneuronal tumour, monosomy 14We read with interest Deng et al.’s 
recent manuscript concerning a newly molecularly defined glioneuro-
nal CNS tumour entity, termed diffuse glioneuronal tumour with oligo-
dendroglioma-like features and nuclear clusters (DGONC).1 DGONCs 
were identified by a distinctive methylation profile that segregated 
away from previously recognised molecular groups of CNS tumours. 
On further review, the authors describe DGONCs as a novel glioneu-
ronal tumour with key neuropathological features including oligoden-
droglioma-like perinuclear halos and nuclear clusters. At a genetic 
level, their cohort of 31 DGONCs was found to have recurrent mono-
somy of chromosome 14 (97%), gain of 1q (26%) and 17q (58%), and 
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loss of 19q (35%), but unlike well-characterised glioneuronal tumours, 
no other defining genetic alterations were identified.
We reviewed our existing paediatric CNS tumour cohorts to 
determine if we could identify additional cases of DGONC. We re-
viewed 123 cases with an undetermined final diagnosis originating 
from two previously described cohorts with existing methylation 
array data.2 From these, we selected tumours that failed to clas-
sify using the most up-to-date version of the methylation classifier 
developed by the DKFZ3 (MNPv11b6) and that had monosomy of 
chromosome 14.1 We then performed unsupervised hierarchical 
clustering using the 10,000 most variably methylated probes for our 
candidate-DGONC samples together with a cohort of 18 DGONC 
reported in the original article,1 along with tumours with a differ-
ent confirmed molecular diagnosis.2,3 Three samples reported were 
found to have methylation profiles with good similarity to Deng 
et al.’s published cases (Figure 1A, labelled GOSH DGONC) and one 
patient was later identified as having a second tumour biopsy taken 
a year later, which also clustered with the reference DGONC cohort.
All patients with a proposed DGONC were male children and, at 
the time of diagnosis, aged between 11 and 12 years. Case DGONC_1 
had been diagnosed as a “malignant glioneuronal tumour”, while 
DGONC_2 and 3 had both been called “high-grade neuroepithelial tu-
mour”. These tumours presented as well-defined cortical or subcortical 
supratentorial masses, and as previously described did not display any 
specific lobar predisposition. From the available radiology (Figure 1C 
and Figure S1), the tumours had no appreciable perilesional oedema, 
were hyperintense compared to cortex on T2 and FLAIR weighting 
and enhanced poorly with contrast if at all. They also demonstrated 
internal matrix calcification, with centrally low ADC values on diffu-
sion-weighted images. Imaging for the relapsed case indicated residual 
tumour but did not show additional radiological features.
All patients are alive and had relatively favourable outcomes, 
although follow-up time following diagnosis varied between only 
0.7 and 6.6 years. Following surgery, all patients received cranio-
spinal radiation together with chemotherapy and are in complete 
remission. All patients received a gross total resection, the additional 
surgery for DGONC_1 was to remove persistent residual tumour fol-
lowing chemotherapy and there was no notable progression on ra-
diology (Figure S1). One patient had a previous diagnosis and family 
history of Autistic Spectrum disorder and Hyperactivity, the other 
two patients had no known underlying conditions.
Morphologically all three cases had remarkably similar charac-
teristics (see Figure 1D-I and Table S1). They were diffusely arranged 
tumours composed of round cells with perinuclear haloes, akin to 
oligodendrogliomas or neurocytic tumours. There were nuclear 
clusters, at least some of which were part of multinucleate cells. 
Calcification, ganglion cells, apoptosis and foamy cells were com-
monly noted. Vascular proliferation was present in two of the four 
samples. The tumours were of moderate cellularity and the mitotic 
index ranged between 0.42 and 3.38 per mm2, with a focal maximum 
of 30% of cells staining positive for Ki67. The tumour cells did not 
express astrocytic markers (e.g. GFAP) but there was diffuse strong 
staining for neuronal markers Synaptophysin and NeuN, as well as 
the oligodendrocyte marker OLIG2. CD34 staining was present in 
the endothelium only. We did not observe histological differences 
between the primary and secondary DGONC_1 sample.
Apart from the methylation arrays, existing molecular workup did 
not identify recurrent molecular events (Table S1). Where data were 
available, no pathogenic variants were observed in the histone H3 
genes, and no pathogenic variants or fusion events were detected 
in BRAF. Targeted panel sequencing on DNA and RNA was available 
for one case (a custom panel4 and Illumina TruSight RNA Pan-Cancer 
fusion Panel, respectively) but failed to reveal any predicted driving 
molecular events. In addition to monosomy of chromosome 14, on 
review of the copy number plots, we noted a common focal loss of 
chromosome 1p (previously not reported) and loss of chromosome 3p.
In conclusion, we have independently identified three DGONCs 
with consistent histopathological, molecular and clinical features 
to those previously described. This study confirms that DGONC 
is a molecularly defined entity with a unique methylation profile 
F I G U R E  1  Summary of presenting features in three paediatric DGONC. (A) DNA methylation profiling of the new DGONC cases with 
existing reference cohorts available online via Heidelberg Molecular Neuropathology platform, https://www.molec ularn europ athol ogy.
org/mnp3 and those held locally with a confirmed molecular classification (calibrated score using MNPb11v6 >0.9).2 FS and DTWJ kindly 
provided reference DGONC samples.1 Samples are coloured according to their methylation class. t-SNE parameters: perplexity = 20, 
theta = 0.5, dims = 2. (B) Representative copy number plot (DGONC_3) showing previously described features of DGONC: monosomy of 
chr14, gains in 1p and 17p. Additionally, we noted focal losses in 1p and 3p that were common in our cases series. (C) Radiological features 
(DGONC_3) of an 11-year-old boy presenting with a mass in the right medial frontal lobe, heterogeneously hyperintense on T2- and FLAIR-
weighted sequences with some internal cysts, poorly enhancing with contrast, and rather heterogeneous on diffusion, with a small focus of 
low ADC values. The CT scan (not shown) revealed calcification in the wall of the cystic area. (D–I) Representative histopathological features 
observed. Predominant features included rounded nuclei with perinuclear haloes (D–E), clear cell morphology, vascular proliferation and 
frequent areas of neutrophil (D–G). We observed nuclear aggregation (E, arrows), giant cells and large foamy cells (G). DGONC were negative 
for glial markers, for example, GFAP (H) and positive for neuronal and oligodendrocyte markers, for example, OLIG2 (I). See extended data 
for summary table of immunohistochemistry available and additional radiology. Abbreviations (A): CN: central neurocytoma, DGONC: 
Diffuse Glioneuronal tumour with Oligodendroglioma-like features and Nuclear Clusters, DLGNT: diffuse leptomeningeal glioneuronal 
tumour, DMG K27: diffuse midline glioma with H3 K27M mutation; EFT CIC: Ewings-like family tumour with CIC alteration; GBM RTKI: 
glioblastoma receptor tyrosine kinase I group; HGNET BCOR: high-grade neuroepithelial tumour with BCOR alteration; HGNET MN1: 
high-grade neuroepithelial tumour with MN1 alteration; LGG DNT: low-grade glioma, dysembryoplastic neuroepithelial tumour; LGG 
MYB: low-grade glioma MYB/MYB1; LGG PA/GG ST: low-grade glioma, hemispheric pilocytic astrocytoma and ganglioglioma; NB FOXR2: 
neuroblastoma with FOXR2 alteration; O IDH: IDH glioma, 1q/19q codeleted oligodendroglioma; DGONC (GOSH): DGONC cases identified 
at our centre (DGONC_1 to DGONC_3, includes DGONC_1R)
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and distinct histopathological features mimicking oligodendrogli-
oma, with the presence of nuclear clusters. All three cases in our 
small series presented at a similar age (11–12 years) and are all male 
children, but we assume that this is coincidental as Deng et al.’s 
larger cohort did not observe a gender bias. Monosomy of chro-
mosome 14 is the main recurrent molecular feature of DGONC, 
and there are no other currently described recurrent pathogenic 
genetic variants.
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